These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21911903)

  • 1. Citrus auraptene: a potential multifunctional therapeutic agent for nonalcoholic fatty liver disease.
    Sahebkar A
    Ann Hepatol; 2011; 10(4):575-7. PubMed ID: 21911903
    [No Abstract]   [Full Text] [Related]  

  • 2. Auraptene and Its Role in Chronic Diseases.
    Derosa G; Maffioli P; Sahebkar A
    Adv Exp Med Biol; 2016; 929():399-407. PubMed ID: 27771936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease.
    Shen L
    Hepatology; 2011 Jul; 54(1):377-8. PubMed ID: 21710476
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges.
    Xiao J; Guo R; Fung ML; Liong EC; Tipoe GL
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):125-35. PubMed ID: 23558065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the pharmacological and therapeutic effects of auraptene.
    Bibak B; Shakeri F; Barreto GE; Keshavarzi Z; Sathyapalan T; Sahebkar A
    Biofactors; 2019 Nov; 45(6):867-879. PubMed ID: 31424600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis.
    Mulvihill EE; Burke AC; Huff MW
    Annu Rev Nutr; 2016 Jul; 36():275-99. PubMed ID: 27146015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lipid droplet as a potential therapeutic target in NAFLD.
    Goh VJ; Silver DL
    Semin Liver Dis; 2013 Nov; 33(4):312-20. PubMed ID: 24222089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages.
    Bieghs V; Rensen PC; Hofker MH; Shiri-Sverdlov R
    Atherosclerosis; 2012 Feb; 220(2):287-93. PubMed ID: 21930273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silymarin and Its Role in Chronic Diseases.
    Neha ; Jaggi AS; Singh N
    Adv Exp Med Biol; 2016; 929():25-44. PubMed ID: 27771919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for nonalcoholic fatty liver disease.
    Moseley RH
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract]   [Full Text] [Related]  

  • 14. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
    Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
    Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug therapy for non-alcoholic steatohepatitis].
    Tomita K; Hibi T
    Nihon Rinsho; 2006 Jun; 64(6):1146-51. PubMed ID: 16768123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of medications for the management of patients with NAFLD.
    Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
    Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder.
    Malnick SD; Beergabel M; Knobler H
    QJM; 2003 Oct; 96(10):699-709. PubMed ID: 14500857
    [No Abstract]   [Full Text] [Related]  

  • 18. [Candidate drugs for non-alcoholic steatohepatitis (NASH)].
    Terai S; Matsumoto T; Sakaida I
    Nihon Yakurigaku Zasshi; 2007 Apr; 129(4):271-5. PubMed ID: 17435339
    [No Abstract]   [Full Text] [Related]  

  • 19. Extract of Citrus maxima (pummelo) leaves improve hepatoprotective activity in Wistar rats submitted to the induction of non-alcoholic hepatic steatosis.
    Feksa DL; Coelho RP; Aparecida da Costa Güllich A; Dal Ponte ES; da Costa Escobar Piccoli J; Manfredini V
    Biomed Pharmacother; 2018 Feb; 98():338-346. PubMed ID: 29274591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
    Qi Z; Xue J; Zhang Y; Wang H; Xie M
    Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.